Fireside Chat: What Each Stakeholder Needs – Repositioning Inflammasome Therapies for Clinical, Commercial & Capital Success
Time: 4:00 pm
day: Conference Day One PM
Details:
- Exploring the rationale for advancing multiple inflammasome-targeting programs in parallel while managing clinical risk through indication diversity
- Outlining key regulatory requirements for inflammasome-targeting therapeutics (safety pharmacology, dosing windows, and MOA validation)
- Shedding light on how successful Phase II data influences Series B/C financing rounds, partnerships, and acquisition strategies
